EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Therapeutic efficacy of zoledronic acid combined with calcium and calcitriol in the treatment of senile osteoporosis in elderly patients

Yi Zhang, Yuan Tian, Xiaojun Chen

Inflammopharmacology · 2025

DOI: 10.1007/s10787-025-01683-4 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Yi Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Geriatric Center, The Fourth People's Hospital of Shenyang, Shenyang, 223400, Liaoning Province, China. Hauptthemen laut MEDLINE: Zoledronic Acid, Osteoporosis, Bone Density Conservation Agents, Calcitriol. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To investigate the effectiveness and safety of combining zoledronic acid with calcium supplements and calcitriol in treating primary osteoporosis in elderly patients. METHODS: Seventy-eight elderly patients with primary osteoporosis were recruited. They were randomly assigned in a 1:1 ratio to either the CC group (calcium carbonate D3 tablets + calcitriol soft capsules) or the CCZ group (calcium carbonate D3 tablets + calcitriol soft capsules + zoledronic acid injection). The treatment duration was 1 year. Bone mineral density (BMD), bone metabolism markers, quality of life (QoL), clinical efficacy, and incidence of adverse reactions (ARs) were assessed. RESULTS: CCZ group showed increased BMD in the lumbar spine (L1~L4 segments), femoral neck, and hip after treatment relative to CC group. Serum levels of bone-specific alkaline phosphatase, cross-linked type 1 collagen C-terminal peptide, and N-terminal propeptide of type 1 procollagen decreased, while osteocalcin levels increased. The QoL Questionnaire of the European Foundation for Osteoporosis scores decreased (P < 0.05 for all comparisons). The clinical effective rates were 76.93% in the CC group and 92.31% in the CCZ group, with AR rates of 23.08% and 12.82%, respectively (P < 0.05 for both). CONCLUSION: Zoledronic acid treatment in elderly patients with primary osteoporosis demonstrates significant efficacy by increasing bone density, improving bone metabolism, enhancing QoL, and exhibiting high safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zoledronic AcidOsteoporosisBone Density Conservation AgentsCalcitriolCalciumHumansFemaleAgedBone DensityMaleQuality of LifeDrug Therapy, CombinationTreatment OutcomeAged, 80 and overCalcium Carbonate

Stichwörter der Autor:innen

Bone densityBone metabolismPrimary osteoporosisQuality of lifeZoledronic acid

Substanzen

Zoledronic AcidBone Density Conservation AgentsCalcitriolCalciumCalcium Carbonate

Autor:innen und Institutionen

  • Geriatric Center, The Fourth People's Hospital of Shenyang, Shenyang, 223400, Liaoning Province, China.
  • Department of Geriatrics, Lianshui County People's Hospital, Huai'an, 223400, Jiangsu Province, China.
  • Department of Orthopedics, Spine Surgery, 907 Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Nanping, 353000, Fujian Province, China. 13960614968@163.comom.

Zitieren

APA

Zhang, Y., Tian, Y., & Chen, X. (2025). Therapeutic efficacy of zoledronic acid combined with calcium and calcitriol in the treatment of senile osteoporosis in elderly patients. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01683-4

Vancouver

Zhang Y, Tian Y, Chen X. Therapeutic efficacy of zoledronic acid combined with calcium and calcitriol in the treatment of senile osteoporosis in elderly patients. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01683-4

BibTeX
@article{Zhang2025,
  author = {Zhang, Yi and Tian, Yuan and Chen, Xiaojun},
  title = {Therapeutic efficacy of zoledronic acid combined with calcium and calcitriol in the treatment of senile osteoporosis in elderly patients},
  journal = {Inflammopharmacology},
  year = {2025},
  doi = {10.1007/s10787-025-01683-4}
}
Kostenlos starten →